AEON Biopharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for AEON Biopharma, Inc. (AEON) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income42.01-384.63-52.56-55.64-32.91
Depreciation & Amortization0.100.100.070.000.00
Stock Based Compensation6.257.005.895.224.79
Change in Working Capital0.71-2.746.271.421.45
Change in Accounts Payable2.52-4.596.61-0.900.67
Change in Other Working Capital-1.821.854.4118.590.79
Other Operating Activities-69.35-15.554.4118.5916.59
Net Cash from Operating Activities-20.29-47.83-35.58-28.43-9.46
Investing Activities
Capital Expenditures0.000.00-0.31-0.170.00
Net Cash from Investing Activities0.000.00-0.31-0.17-1.27
Financing Activities
Debt Repayment15.000.00-3.990.00-0.30
Common Stock Issued0.150.000.000.000.00
Other Financing Activities0.000.000.00-1.44-0.54
Net Cash from Financing Activities15.1514.0040.5113.5624.57
Summary
Net Change in Cash-5.15-33.834.62-15.0413.84
Cash at Beginning of Period5.1624.055.1320.170.00
Cash at End of Period0.01-320.149.755.130.00
Free Cash Flow-20.29-47.83-35.89-28.60-9.46